Treatment of UTI with ESBL Klebsiella pneumoniae Bacteremia

First-Line Treatment Options

The Infectious Diseases Society of America recommends ceftazidime/avibactam (2.5g IV every 8 hours) as first-line therapy for infections caused by ESBL-producing Klebsiella pneumoniae with bacteremia 1, 2, 3
Meropenem/vaborbactam (2g IV every 8 hours) is an equally effective first-line option with strong recommendation and moderate certainty of evidence 2, 3
Treatment duration should be 10-14 days for bacteremic UTIs, with consideration for longer duration based on clinical response 4, 5

Imipenem/relebactam may be considered as an alternative when first-line agents are unavailable (conditional recommendation, low certainty of evidence) 2, 3
Cefiderocol is another alternative option that can be considered when first-line agents cannot be used 2, 3
Carbapenems (ertapenem, meropenem, imipenem) remain effective against most ESBL-producing organisms but should be used judiciously to prevent development of carbapenem resistance 5

Rapid testing strategies to identify specific resistance mechanisms are strongly recommended to guide appropriate antibiotic therapy early 1, 3
Susceptibility testing is essential as ESBL-producing K. pneumoniae may have variable resistance patterns 6
Blood cultures should be repeated to document clearance of bacteremia 5

Healthcare-associated infections and recent hospitalization increase the risk of ESBL-producing organisms 6

Traditional antibiotic regimens including colistin have shown poor efficacy and unfavorable toxicity profiles compared to newer agents 2, 3

The recommendations for using ceftazidime/avibactam and meropenem/vaborbactam are based on observational studies with moderate certainty of evidence 2, 3
Real-world experience has demonstrated significant benefits of these newer agents over traditional antibiotic regimens in terms of clinical efficacy and safety 1, 2
Patients with KPC-producing K. pneumoniae bloodstream infections treated with ceftazidime/avibactam had significantly lower 28-day mortality compared to those treated with other active agents (18.3% vs. 40.8%, p=0.005) 2